Review

“You cannot stay in the laboratory forever”*: Taking pig kidney xenotransplantation from the laboratory to the clinic

David K.C. Cooper*, Hidetaka Hara

Xenotransplantation Program, Division of Transplantation, Department of Surgery, University of Alabama at Birmingham, 752 Lyons-Harrison Research Building, 701 19th Street South, Birmingham, AL 35294, USA

ARTICLE INFO

Article History:
Received 8 June 2021
Revised 2 August 2021
Accepted 16 August 2021
Available online xxx

Keywords:
Kidney
Nonhuman primate
Patient selection
Pig, genetically-engineered
Xenotransplantation
Clinical
Preclinical

ABSTRACT

Progress in life-supporting kidney transplantation in the genetically-engineered pig-to-nonhuman primate model has been encouraging, with pig kidneys sometimes supporting life for > 1 year. What steps need to be taken by (i) the laboratory team, and (ii) the clinical team to prepare for the first clinical trial? The major topics include (i) what currently-available genetic modifications are optimal to reduce the possibility of graft rejection, (ii) what immunosuppressive therapeutic regimen is optimal, and (iii) what steps need to be taken to minimize the risk of transfer of an infectious microorganism with the graft. We suggest that patients who are unlikely to live long enough to receive a kidney from a deceased human donor would benefit from the opportunity of a period of dialysis-free support by a pig kidney, and the experience gained would enable xenotransplantation to progress much more rapidly than if we remain in the laboratory.

© 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Progress in life-supporting kidney and heart transplantation in genetically-engineered pig-to-nonhuman primate (NHP) models has been encouraging, with pig kidneys supporting life for > 1 year [1,2], and pig hearts for > 6 months [3,4]. (Much less progress has been achieved with pig liver and lung xenotransplantation.) As a result, attention is now being directed to planning the initial clinical trials [5].

It is therefore important to consider what steps need to be taken (i) by the laboratory team in preparation for the first clinical trials, and (ii) by the clinical team to prepare for the first trial, e.g., the selection of the first patients who ethically might be offered a pig organ. We suggest that it is unrealistic to anticipate uniformly great prolongation (i.e., several years) of graft and recipient survival after clinical pig kidney or heart transplantation (although this may occur in some patients, as it did after the early kidney and heart allotransplantation), but there is every reason to believe that a pig organ could act as an effective relatively long-term bridge to allotransplantation.

Although this approach would not immediately increase the number of ‘donor’ organs available, it would at least maintain life while the patient awaited a suitable allograft (just as dialysis and ventricular assist devices do today). Even if not every patient can be maintained until a suitable allograft becomes available, the experience gained would be valuable in determining the problems that need to be overcome if xenotransplantation is to progress to destination therapy.

For a number of reasons, we suggest that the first clinical trial should be of pig kidney, rather than heart, transplantation [9]. Important considerations include the fact that, if the pig graft fails from rejection, or if the patient develops a life-threatening systemic infection that is resistant to the available therapy, the kidney can be excised, all immunosuppressive therapy discontinued, and dialysis recommenced. Comparable rescue therapy is less easily available to a patient whose pig heart has failed completely. Hereafter, therefore, we shall direct our comments to a first clinical trial of pig kidney transplantation.

The national regulatory authorities are likely to require the demonstration of ‘complication-free’ survival of a life-supporting pig kidney in a NHP for 6 months or longer in a series of at least 6 consecutive experiments before a clinical trial would be considered appropriate. ‘Complication-free’ implies absence of irreversible rejection or life-threatening infection, and without features of severe rejection.

Abbreviations: CMV, Cytomegalovirus; NHP, Nonhuman primate; TKO, Triple-Knockout (i.e., in a pig in which the three known carbohydrate xenoantigens have been deleted).

(Quote by Christina N. Barnard, MD, the surgeon who carried out the world’s first human-to-human heart transplant in 1967).

* Corresponding author.
E-mail address: dicooper@uabmc.edu (D.K.C. Cooper).
rejection on graft biopsies or of chronic infection or de novo neoplasia at necropsy. Some may consider 6 months to be too short a period to indicate longer survival in a human patient, but maintaining immunosuppressed NHPs consistently for long periods is much more difficult than managing a patient in a hospital setting. NHPs have unhygienic habits, cannot communicate any symptoms they might be experiencing, and the sophisticated facilities of hospitals, including intensive care units, cannot be replicated in an animal facility.

What do we need to do to provide these relevant experimental data to the regulatory authorities?

2. Search strategy and selection criteria

Data for this Review were identified by searches of MEDLINE, Current Contents, PubMed, and references from relevant articles using the search terms “xenotransplantation”, “kidney”, “pig”, and “nonhuman primate”. With few exceptions, only articles published in English between 1990 and 2021 were included.

3. The preclinical model

3.1. The recipient NHP

Baboons and other Old World monkeys (e.g., rhesus, cynomolgus) are currently being used experimentally as recipients of pig organ grafts. There is no conclusive evidence that one of these species provides any immunological advantage over others.

3.2. The organ-source pig

Two major topics need to be considered, namely (i) what (currently-available) genetic modifications are optimal to reduce the possibility of rejection of the graft, and (ii) what steps need to be taken to minimize the risk of the transfer of an infectious microorganism with the graft to the immunosuppressed recipient, and possibly into the community.

There has been an evolution of techniques for the genetic engineering of pigs during the past 3 decades (Table 1). A wide range of genetically-engineered pigs has been provided or proposed as organ-sources for experimental studies (Table 2), thus making results between studies (or even within a single study) difficult to compare. It is time for the optimal genetically-engineered organ-source pig (given our present knowledge) to be identified, and only organs from these specific pigs transplanted. The exact phenotype of the pig should be confirmed in vitro before an in vivo study is carried out [10].

It needs to be borne in mind that the regulatory authorities will expect a justification for each genetic manipulation included, and it should also be realized that each genetic manipulation brings with it a potential risk of introducing new problems, and thus may be detrimental to progress. For the first clinical trials, therefore, as long as they are effective in protecting the graft from the primate innate immune response, the fewer the number of genetic manipulations maybe the better.

Table 1.
Timeline for application of evolving techniques for genetic engineering of pigs employed in xenotransplantation.

| Year | Technique |
|------|-----------|
| 1992 | Microinjection of randomly-integrating transgenes |
| 2000 | Somatic cell nuclear transfer (SCNT) |
| 2002 | Homologous recombination |
| 2011 | Zinc finger nucleases (ZFNs) |
| 2013 | Transcription activator-like effector nucleases (TALENs) |
| 2014 | CRISPR/Cas9* |

*CRISPR/Cas9 = clustered randomly interspaced short palindromic repeats and the associated protein 9.

Currently, most groups agree that deletion of expression of the three known carbohydrate xenoantigens expressed in pigs against which humans have natural (preformed) antibodies (Gal, Neu5Gc, Sda, i.e., triple-knockout (TKO) pigs [Table 3]) [11–16] will be important for any clinical trial. Human infants do not make natural antibodies against TKO pig cells [17], and even many adults do not have antibodies against these cells (Fig. 1). However, experimental studies are greatly complicated by the fact that all NHPs have natural antibodies to TKO pig cells [16,18]. Furthermore, these antibodies in NHPs are associated with a very high level of complement-dependent cytotoxicity (Fig. 1) [18].

Some investigators believe that organs from TKO pigs may alone be sufficient for the first clinical trial, but we suggest that the graft may still be at risk from complement injury associated with such events as ischaemia-reperfusion or a systemic infection, or other factors, and so it would seem wise for the graft to express one or more human complement-regulatory proteins, e.g., CD46, CD55, CD59, which are largely effective in protecting a pig graft from the effects of human complement [19–24].

Table 2.
Selected genetically-modified pigs produced for xenotransplantation research.*

| Antigen (omit ‘or’deletion or ‘masking’ | |
|--------------------------------------|---|
| human H-transferase gene expression (expression of blood type O antigen) | |
| endo-beta-galactosidase C (reduction of Gal antigen expression) | |
| α1,3-galactosyltransferase gene-knockout (GTKO) | |
| cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene-knockout (NeuGc-KO) | |
| β4GalNT2 (β1,4 N-acetylgalactosaminyltransferase) gene-knockout (β4GalNT2-KO) | |

Complement regulation by human complement-regulatory gene expression

| CD46 (membrane cofactor protein) | |
| CD55 (decay-accelerating factor) | |
| CD59 (protectin or membrane inhibitor of reactive lysis) | |

Anticoagilation and anti-inflammatory gene expression or deletion

| von Willebrand factor (VWF) (deficient) | |
| human tissue factor pathway inhibitor (TFPI) | |
| human thrombomodulin | |
| human endothelial protein C receptor (EPCR) | |
| human CD39 (ectonucleoside triphosphate diphosphohydrolase-1) | |

Anticoagulation, anti-inflammatory, and anti-apoptotic gene expression

| human A20 (tumor necrosis factor-alpha-induced protein 3) | |
| human heme oxygenase-1 (HO-1) | |

Inhibition of phagocytosis

| human CD47 (species-specific interaction with SIRPa inhibits phagocytosis) | |
| porcine asialoglycoprotein receptor 1 gene-knockout (ASGR1-KO) (decreases platelet phagocytosis) | |
| human signal regulatory protein α (SIRPa) (decreases platelet phagocytosis by ‘self’ recognition) | |

Suppression of cellular immune response by gene expression or downregulation

| CBI1A-DN (MHC class II transactivator knockout, resulting in swine leukocyte antigen class II knockdown) | |
| Class I MHC-knockout (MHC-I-KO) | |
| HLA-E/human β2-microglobulin (inhibits human natural killer cell cytotoxicity) | |
| HLA-G | |
| human FAS ligand (CD95L) | |
| human GaST-III (N-acetylgalactosaminyltransferase III) gene | |
| porcine CTL4A-Ig (Cytotoxic T-Lymphocyte Antigen 4 or CD152) | |
| human TRAIL (tumor necrosis factor-alpha-related apoptosis-inducing ligand) | |
| Programmed death-ligand 1 (PD-L1) | |

Prevention of porcine endogenous retrovirus (PERV) activation

| PERV siRNA | |
| PERV-KO | |

*Based on an original list compiled by Ekser B²⁴.
The well-described incompatibilities in the coagulation systems between pigs and primates, highlighted originally by the groups of Platt [25], Robson [26,27], d’Apice [28,29], and others [30–32], also suggest that expression of at least one human coagulation-regulatory protein (e.g., thrombomodulin [TBM], endothelial protein C receptor [EPCR], tissue factor pathway inhibitor [TFPI]) is beneficial in NHPs in preventing the development of thrombotic microangiopathy in the graft and consumptive coagulopathy in the recipient [33,34].

The increasing evidence for a sustained systemic inflammatory response to the graft [35] suggests that expression of one or more human anti-inflammatory (anti-apoptotic) proteins, e.g., haemoxynogenase-1, A20, may also be advantageous [34]. There is also evidence that inhibition of the human macrophage response to pig cells by the expression of human CD47 in the organ-source pig may be beneficial [34].

There are several other genetic manipulations that could be included (Table 2), but many of these relate to reducing the effect of the adaptive immune response, rather than the innate response. The adaptive response can generally be suppressed by an effective immunosuppressive regimen (see below), and therefore additional genetic-engineering directed to this response may not be essential to demonstrate efficacy in the first clinical trials. Further manipulations could include knockout or knockdown of expression of swine leukocyte antigens (SLA) class I and/or II, and expression of CTLA4–Ig or PD-L1 in the graft, any of which would likely reduce the strength of the adaptive immune response, but may be associated with features of immunodeficiency in the pig [36] or possibly a susceptibility to infectious complications, e.g., of herpesviruses, in the pig organ graft itself.

The technique of genetic-engineering of the pigs is obviously very important, e.g., with regard to whether a ubiquitous or endospecific promoter is used, and whether bicistronic or multicistronic vectors are employed [37] (Figs. 2 and 3). It is important that a human transgene should be well-expressed, but over-expression can result in complications, e.g., a bleeding tendency in the pig if expression of human coagulation-regulatory proteins is excessive.

There are several other areas where genetic engineering of the pig may play a role. Two of these are of particular interest.

As the potential risks of the presence of porcine endogenous retroviruses (PERVs) in the pig remain unknown (though likely low), inactivation of these viruses [38,39], or inhibition of expression of PERV [40,41], is clearly an advantage. Such a genetic manipulation would remove the long-standing concern that PERVs may be pathogenic in humans, or may combine with fragments of human endogenous retroviruses to form new viruses. To our knowledge, to date only one group is combining PERV-knockout with the genetic manipulations required to resist the innate immune response [38].

After life-supporting pig kidney (or heart) transplantation in baboons, rapid growth of the organ has been documented within the first few months, suggesting that innate factors, e.g., a persistence of pig growth hormone, remain functioning in the graft during this period of time. After approximately 3 months, this rapid growth declines and subsequent growth of the organ is comparable to that of the native baboon organs [33,42–44]. Although in our experience a rapidly-growing pig kidney can be accommodated within the flexible confines of the recipient abdomen (possibly because rapamycin, which inhibits growth, is a constituent of the immunosuppressive regimen we administer) [33,44], one group has reported ischaemic injury associated with compression of the kidney graft within the abdomen [45,46].

The experiments in which this problem has been observed have used genetically-engineered domestic pigs, e.g., Large White/Landrace, as the source of the organs. If a breed of miniature swine, e.g.,

---

Table 3. Carbohydrate xenoantigens that have been deleted in genetically-engineered pigs.

| Carbohydrate (Abbreviation) | Responsible enzyme | Gene-knockout pig |
|-----------------------------|--------------------|-------------------|
| 1. Galactose-α1,3-galactose (Gal) | α1,3-galactosyltransferase | GTKO |
| 2. N-glycolyneuraminic acid (Neu5Gc) | Cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) | CMAH-KO |
| 3. Sda | β-1,4N-acetylgalactosaminyltransferase/4GalNT2-KO |

---

**Fig. 1.** Human (top) and Old World monkey (OWM) (bottom) IgM (left) and IgG (middle) binding and complement-dependent cytotoxicity (CDC, at 25% serum concentration) (right) to wild-type (WT), GTKO, and TKO pig PBMCs. Results are expressed as mean ± SEM. (*p < 0.05, **p < 0.01; N.S. = not significant). On the y axis, the dotted line represents cut-off value of binding (relative GM: IgM 1.2, IgG 1.1), below which there is no binding. For CDC on the y axis, the dotted line represents cut-off value of cytotoxicity (6.4%), below which there is no cytotoxicity. (Note the difference in scale on the y axis between IgM and IgG.) (Reprinted with permission from Yamamoto T, et al. 2020).
Yucatan, were the source, the problem might be prevented or mini-
mized. However, minipigs, and especially Yucatan, may be character-
ized by high expression of PERV in different organs [47,48]. An
alternative approach, suggested by Hinrichs et al. [49-51], is to delete
expression of growth hormone receptors in the pig. This has been
carried out [51].

4. The immunosuppressive regimen

It is important that forthcoming preclinical experience is directly rel-
evant to the first clinical trials. Most groups have followed the lead set
by Buhler et al by combining T cell depletion with blockade of the
CD40/CD154 costimulation pathway (Table 4) [52,53]. Conventional
maintenance immunosuppressive therapy, e.g., tacrolimus-based, has
proven insufficient in pig organ xenotransplantation [52,54], and block-
ade of the CD28/B7 costimulation pathway has also been unsuccessful
[54,55]. The current evidence is that CD40/CD154 costimulation path-
way blockade is not associated with a greater incidence of drug-related
complications than conventional immunosuppressive therapy.

However, the choice and sources of the agents and/or the dosages
have varied [56]. Despite the expression of one or more human com-
plement-regulatory proteins on the vascular endothelium of the pig
organ, a case can be made for induction therapy with a complement
inhibitor, e.g., a C1-esterase inhibitor, as initial systemic complement
activation, possibly associated with ischaemia-reperfusion injury,
may prove detrimental to graft outcome. There is evidence that
blockade by an anti-CD154 agent (if non-thrombogenic) is associated
with a better outcome than blockade by an anti-CD40 agent [57,58],
but progress has been limited until recently by the unavailability of
such agents. To our knowledge, though several anti-CD154 agents
are currently in clinical trials for autoimmune disease [56], none of
them is yet approved by the regulatory authorities. It remains uncer-
tain whether they will be approved for clinical trials of xenotrans-
plantation, but we suggest that preclinical studies should progress
with the anticipation that one or more of the anti-CD154 agents will
become approved.

This therapy is usually combined with a conventional immuno-
suppressive drug, e.g., mycophenolate mofetil, rapamycin, or tacrol-
imus, and a corticosteroid, but there is some evidence that corticosteroids may be unnecessary [59], particularly as they do not
suppress the inflammatory response to a xenograft (see below) [35].
Furthermore, there is no conclusive evidence that even the secondary
immunosuppressive agent, e.g., mycophenolate mofetil, is essential,
as no group has hitherto relied on CD40/CD154 pathway blockade
alone.

Just as each group involved in this field of research is using
slightly different organ-source pigs for their studies, so are they also
using slightly different immunosuppressive regimens. Comparison of
the results of the studies between various investigators is therefore
difficult or impossible, as there are so many variables. If satisfactory
data are to be obtained for the regulatory authorities, future studies
need to be more consistently focused on a specific genetically-engi-
eered pig and a specific immunosuppressive regimen.

5. Anti-inflammatory therapy

There is convincing evidence of a systemic inflammatory response
that follows pig organ transplantation in a NHP [35], and this is
another topic that requires decisions. Is anti-inflammatory therapy
necessary? There is no definite answer to this question as yet, in part
because this therapy has been added to various immunosuppressive
regimens and administered to NHPs receiving grafts from different
genetically-engineered pigs. Without confirmatory evidence of bene-
fit, agents such as TNF inhibitors, e.g., etanercept, and IL-6 inhibitors,
e.g., tocilizumab (that prevents IL-6 binding to baboon tissues, but
not to pig tissues [60]) have sometimes been included in the regimen.
Conclusive evidence for their benefit needs to be provided.

6. Adjunctive therapy

Because of the high risk of the development of thrombotic micro-
angiopathy and consumptive coagulopathy seen in the early days of
research into xenotransplantation [31,32], some groups administer anti-platelet therapy and/or systemic anticoagulation to the recipient throughout part or all of the post-transplant period. Whether this is necessary if the graft expresses one or more human coagulation-regulatory proteins remains unknown, although probably neither therapy is detrimental.

7. The potential risk of infectious complications

Before a clinical trial can be undertaken, it will be necessary to determine how the risk of transfer of an exogenous infectious agent with the pig organ can be minimized. This will largely be achieved by breeding and maintaining ‘designated pathogen-free’ pigs [61] in a biosecure ‘super-clean’ facility [62]. Based on experience in immuno-suppressed humans undergoing organ allotransplantation, in some pig-to-NHP organ transplant studies, prophylaxis is administered to prevent NHP cytomegalovirus (CMV) activation and infection by pneumocystis (Table 4). It should be noted, however, that ganciclovir and valganciclovir are relatively ineffective against porcine CMV [63].

In our recent studies, both the recipient baboons (Michale E. Keeling Center, Bastrop, TX) and the organ-source pigs (Revivicor, Blacksburg, VA) have been bred and raised to be CMV-negative, and a strong case could be made that prophylaxis for CMV is no longer required. In clinical trials, however, the patient may be CMV-positive, and so prophylaxis to prevent activation of human CMV will probably follow current clinical practice in this respect.

8. Diagnosis of pig kidney graft rejection

Until pigs became available that expressed human coagulation-regulatory proteins, rejection of pig kidney (and heart) grafts in NHPs could be clearly diagnosed by rapid reductions in platelet count and plasma fibrinogen as thrombotic microangiopathy developed in the graft [31–34,64]. With the availability of more advanced genetically-engineered pigs as sources of the grafts, these markers of rejection are no longer valid.

Today, the clinical features of rejection of a pig kidney are similar to those seen in clinical kidney allotransplantation, namely a rise in serum creatinine, increased proteinuria, and decreased renal blood flow on ultrasound examination. This is an important advance because physicians with experience in caring for patients with a kidney allotransplant will now be able to use that experience in the management of patients with a pig kidney xenotransplant. Both episodes of rejection and hypovolemia (see below) [65] are associated...
with a rise in serum creatinine, but can be differentiated because, in our experience, proteinuria only increases when rejection is occurring. Changes in urine output have not proven informative.

Immunological markers are not of great value in detecting rejection after pig kidney (or heart) xenotransplantation. Increases in serum anti-pig antibodies are usually not detectable because they bind to the graft, and only become obvious when it is possible for the graft to be excised, e.g., in the case of a heterotopic (non-life-supporting) pig heart. In our experience, when an immunosuppressive regimen based on blockade of the CD40/CD154 costimulation pathway has been administered (Table 4), post-transplantation T and B cell numbers remain at 30–40% of their baseline numbers, and are non-informative with regard to the development of rejection. There is hope, however, that methods such as the detection of cell-free pig DNA using integrated PERV sequences may prove useful in monitoring graft damage/rejection [66].

There are currently no data to determine whether changes in glomerular filtration rate correlate with the onset of rejection. Because of the relative absence of good markers of rejection, needle biopsies of the graft may need to be carried out more frequently after kidney xenotransplantation than is currently necessary after allotransplantation. Histopathological features of rejection include glomerular injury and some thrombotic microangiopathy (Foote JB, et al, submitted).

### Table 4.
A representative immunosuppressive, anti-inflammatory, and adjunctive drug regimen used in pig-to-baboon kidney transplantation experiments at our center.

| Agent | Dose (duration) |
|-------|-----------------|
| **Induction** | |
| Thymoglobulin (ATG) (Genzyme, Cambridge, MA) | 5 mg/kg i.v. (days -3 and -1) (to reduce the CD3+ T cell count to < 500/mm³) |
| Anti-CD20 mAb (rituximab) (Genentech, South San Francisco, CA) | 17.5 U/kg i.v. (days 0, 1, 7 and 14) |
| C1-esterase inhibitor (Berinert, CSL Behring, King of Prussia, PA) | 50 mg/kg (days -1, 0, 4, 7, 14, and weekly) |
| **Maintenance** | |
| Anti-CD40 monoclonal antibody (mAb) (2C10R4, a chimeric rhesus IgG4) (NIH NHP Resource Center, Boston, MA) | |
| Rapamycin (Rapa) (LC Laboratories, Wooburn, MA) | 0.01-0.04 mg/kg i.m. × 2/d (target trough 6-10 ng/ml), beginning on day -4. |
| Methylprednisolone (Astellas, Deerfield, IL) | 5 mg/kg/d on day 0, tapering to 0.125 mg/kg/d by day 7. |
| **Anti-inflammatory** | |
| Etoracet (TNF-α antagonist) (Amgen, Thousand Oaks, CA) | 1 mg/kg (day 0), 0.5 mg/kg i.v. (days 3, 7, 10) |
| **Adjunctive** | |
| Aspirin (Bayer, Deland, FL) | 40 mg p.o. (alternate days), beginning on day 4. |
| Low molecular weight heparin (LMWH) (Eisai, Woodcliff Lake, NJ) | 700 IU/d s.c., beginning of day 1. |
| Erythropoetin (Amgen) | 500 U i.v. weekly, beginning on day -4 |
| Ganciclovir (Genentech) | 5 mg/kg/d i.v., from day -4 to day 14 and when the baboon is sedated for blood draws (x2 weekly). |
| Valganciclovir (Genentech) | 15 mg/kg/d p.o., beginning on day 15 |
| Sulfamethoxazole and trimethoprim (Teva, North Wales, PA) | 10 mg/kg i.v. / d, on days 4-14 |
| Sulfamethoxazole and trimethoprim oral suspension (Akorn, Lake Forest, IL) | 75 mg/m² p.o x2/day, x3 weekly, beginning on day 15. |

9. **Functional aspects of life-supporting pig kidneys in nonhuman primates**

To our knowledge there have been no detailed studies of pig kidney function in a NHP recipient, but those NHPs that have survived for several months or longer have not provided evidence of major deficiencies in this respect [1,2,33,43,44]. Furthermore, as the availability of pig kidneys will ultimately be limitless, there is no reason why a patient should not be provided with two kidneys, rather than one as in allotransplantation. With two kidneys, good renal function may be sustained over a longer period of time.

An impaired renin-angiotensin-aldosterone system (RAAS) is one explanation for the episodes of hypovolemia that have been reported in baboons [44,65] (Fig. 4). Since decreased renin activity may be a factor, if porcine renin is confirmed not to cleave human or NHP angiotensinogen at a clinically significant rate, consideration may need to be given to generating pigs that express human renin. If other significant functional differences are identified, these could possibly also be resolved by judicious genetic engineering of the pig.

10. **The first clinical trial**

Although pig-to-NHP models have provided valuable information, these models have many limitations, one of which is the presence of antibodies to TKO pig cells, as mentioned above. Another is the lack...
of functional receptors for PERVs in NHPs, negating the value of observations on the potential complications of PERVs in pig-to-NHP models [67]. We firmly believe that progress will advance more rapidly when clinical trials take place.

Our proposal is that the first clinical trial of pig kidney transplantation should be limited to only four carefully-selected patients over the course of one year. If, after the first transplant, the patient remains well for three months with good renal function and an absence of major complications, e.g., infection, then the second patient would be added to the trial. All four patients would be followed for one year, at which time, in collaboration with the regulatory authorities, a decision would be made on expanding the trial.

11. Selection of patients

In the USA, the median waiting time for a deceased human kidney (approximately 4 years) indicates the time it will take for half of the potential recipients to undergo kidney transplantation. Patients removed from the wait-list are not included in the calculation. Importantly, information on median wait-time obscures the fact that, because of death or being removed from the wait-list because they are no longer acceptable recipients, a significant percentage of candidates (approximately 40%) never receive an allograft.

On the basis that the period on the wait-list might be so long that they may die before being allocated a deceased human donor organ, we have suggested that older age patients (55–60 years or possibly 55–65 years), but with good physiology and no serious comorbidities, particularly if of blood group O (as these patients tend to spend longer on the wait-list), should be considered as potential candidates for the first clinical trial [69]. As the anticipated period of pig graft survival remains uncertain, younger patients, who are more likely to survive until a suitable allograft becomes available, should perhaps be excluded from the initial trials.

We suggest that the patients should have been initiated on chronic hemodialysis (and should not undergo pre-emptive kidney xenotransplantation, i.e., before requiring dialysis) because the patient and his/her family should be convinced that kidney failure has progressed to the point where death would have occurred if dialysis had not been initiated. Other factors could also be considered, e.g., patients (i) who no longer have vascular access to enable hemodialysis, or (ii) with recurrent kidney disease after allotransplantation, but we suggest that these patients are less suitable because they have likely been on dialysis for a long period of time (and, therefore, have possibly developed comorbidities) and/or have undergone previous kidney allotransplantation, both of which conditions might complicate the management of the patient in an initial clinical trial. With few differences, exclusion criteria for the first patients should be based on those for selection for allotransplantation, and have been documented elsewhere [68].

12. Immunologic aspects of patient selection

Potential human recipients should be selected who do not have (i) anti-glycan IgM/IgG (i.e., anti-TKO pig) antibodies or evidence of serum cytotoxicity to cells from the organ-source pig, (ii) antibodies directed to human leukocyte antigens (i.e., anti-HLA antibodies) that may cross-react with swine leukocyte antigens [SLA], and (iii) a particularly strong response on mixed lymphocyte reaction (compared to the median response of a panel of potential recipients) [69].

Patients with high calculated panel-reactive antibodies (cPRA) (i.e., anti-HLA antibodies), for whom it will be difficult to identify an acceptable deceased human donor, will be strong future candidates for xenotransplantation. However, although the majority of HLA-sensitized patients do not appear to have antibodies that cross-react with SLA [70–72], there is evidence that some do, which would increase the risk of antibody-mediated rejection of the pig organ [73,74]. A very recent study suggested that pig kidney graft survival was shorter in allosensitized monkeys than in non-sensitized monkeys [75].

Studies by Martens, Ladowski, and their colleagues indicated that sera from some sensitized humans may possess cross-reactive anti-HLA antibodies capable of binding to SLA in epitope-restricted patterns [74,76,77]. Importantly, single amino-acid mutagenesis of the HLA-SLA epitope by genetic engineering, for example mutation of an arginine to a proline in the SLA molecule, significantly decreased or completely eliminated antibody binding for a majority of tested samples [76,77]. However, there were exceptions to this approach. For one SLA class II epitope, the antibody binding was limited to the epitope, and was unchanged despite mutations made to the surrounding amino acids [77].

Although HLA-sensitized patients may ultimately benefit most from the availability of pig kidney xenografts, we suggest that they should not be considered for the first clinical trial. However, the novel methods of genetic engineering being explored offer the prospect of overcoming this problem in the future, enabling even HLA-highly-sensitized patients to undergo xenotransplantation with no additional risk of graft rejection.

The current (limited, but increasing) evidence suggests that sensitization to pig antigens, should it develop after pig organ transplantation, would not be detrimental to the outcome of a subsequent allotransplant [78,79]. If confirmed, this is a very important point as it would not preclude subsequent successful allotransplantation after an initial bridging xenotransplant. A patient undergoing pig kidney transplantation could remain on the wait-list for a deceased human allograft and, at least for a period of time (as yet uncertain), avoid the medical and social disadvantages of chronic dialysis, and enjoy the benefits of a functioning kidney graft. The experience gained by such a clinical trial would provide valuable data that would enable progression to pig kidney transplantation as destination therapy.

13. Public opinion

Ethical and social aspects of xenotransplantation also need to be considered. The opinions of patients, health care professionals, and members of the public need to be sought. A number of surveys and focus groups have been organized by Paris and his colleagues during the past three years, which indicate that the public is largely supportive of xenotransplantation [80–86]. The influence of religious beliefs has also been explored [87,88].
14. Conclusions

Although data regarding genetically-engineered pig kidney transplantation in NHPs are steadily accumulating, numerous details need to be clarified before the regulatory authorities can be provided with definitive data to support a clinical trial of xenotransplantation. The two most important areas that need attention are (i) what pig genetic materials are necessary, and (ii) what immunosuppressive/anti-inflammatory/adjunctive therapeutic regimen is optimal to offer success. Decisions will be based on current and future experience in the laboratory, but must be applicable to clinical xenotransplantation.

Outstanding questions

The most important are (i) what genetic manipulations in the pig are considered essential or highly beneficial to protect against the innate immune response, and (ii) what drug therapy is necessary for the recipient to prevent the adaptive immune response.

Declaration of Competing Interest

The authors have no conflicts of interest.

Acknowledgements

Work on xenotransplantation at the University of Alabama at Birmingham is supported in part by NIH NIAID U19 Grant AI090959, and in part by a Department of Defense Grant W81XWH2010559.

References

[1] Adams AB, Kim SC, Martens GR, et al. Xenoantigen deletion and chemical immunosuppression can prolong renal xenograft survival. Ann Surg 2018;268:564–73.
[2] Kim SC, Mathews DV, Breeden CP, et al. Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion. Am J Transplant 2019;19:2174–85.
[3] Langin M, Mayr T, Reichert B, et al. Consistent success in life-supporting porcine cardiac xenotransplantation. Nature 2018;564:430–3.
[4] Cleveland DC, Jagdale A, Carlo WF, et al. The genetically engineered heart as a bridge to allotransplantation in infants: just around the corner? Ann Thorac Surg 2020;109:1268–73.
[5] Good AH, Cooper DKC, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in man. Transplant Proc 1992;24:559–62.
[6] Cooper DKC, Koren E, Oriol R. Genetically engineered pigs. Lancet 1993;342:682–5.
[7] Li P, Walsh JR, Lopez K, et al. Genetic engineering of porcine endothelial cell lines for clinical kidney or heart xenotransplantation. Xenotransplantation 2015;22:302–7.
[8] Cooper DKC. Christiaan Barnard and his contributions to heart transplantation. J Heart Lung Transplant 2001;20:599–610.
[9] Cooper DKC, Cleveland DC. The first clinical trial – kidney or heart? Xenotransplantation 2020;27(2):e12644. Dec18. doi:10.1111/xen.12644.
[10] Li P, Walsh JR, Lopez K, et al. Genetic engineering of porcine endothelial cell lines for evaluation of human-to-pig xenoreactive immune responses. Sci Rep 2021;11:13131. doi:10.1038/s41598-021-92543-y.
[11] Good AH, Cooper DRC, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in man. Transplant Proc 1992;24:559–62.
[12] Cooper DRC. The case for xenotransplantation. Clin Transplant 2015;29:288–93.
[13] Starzl TE. History of clinical transplantation. World J Surg 2000;24:759–82.
[14] Robbins RC, Barlow CW, Oyer PE, et al. Thirty years of cardiac transplantation at Stanford university. J Thorac Cardiovasc Surg 1999;117:939–51.
[15] Cooper DRC. Christiaan Barnard and his contributions to heart transplantation. J Heart Lung Transplant 2001;20:599–610.
[16] Cooper DRC, Cleveland DC. The first clinical trial – kidney or heart? Xenotransplantation 2020;27(2):e12644. Dec18. doi:10.1111/xen.12644.
[17] Li P, Walsh JR, Lopez K, et al. Genetic engineering of porcine endothelial cell lines for evaluation of human-to-pig xenoreactive immune responses. Sci Rep 2021;11:13131. doi:10.1038/s41598-021-92543-y.
[18] Yamamoto T, Iwase H, Patel D, et al. Old World monkeys are less than ideal transgenic pigs for potential organ donors for humans. Nat Med 1995;1:964–6.
[19] Cooper DRC, Esker B, Ramsoordar J, Phelps C, Ayares D. The role of genetically-engineered pigs in xenotransplantation research. J Pathol 2015;238:288–99 Sep 142016. doi:10.1002/path.4633.
[20] Robson SC, Cooper DRC. d’Apice AJ. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 2000;7:166–73.
[21] d’Apice AJ, Cowan PJ. Profound coagulopathy associated with pig-to-primate xenotransplants: how many transgenes will be required to overcome this new barrier? Transplantation 2000;70:1273–4.
[22] Cowan PJ, Anjum A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are hypercoagulable but can coagulate in non-immunosuppressed baboons. Transplantation 2000;69:2504–15.
[23] Kozlowski T, Shimizu A, Lambrits D, et al. Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Transplantation 1999;67:18–30.
[24] Bührer L, Basker M, Alwayn IPJ, et al. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000;70:1323–31.
[25] Knosalla C, Gollackner B, Bührer L, et al. Correlation of biochemical and hematological changes with graft failure following pig heart and kidney transplantation in baboons. Am J Transplant 2003;3:1510–9.
[26] Iwase H, Hara H, Ezzelarab M, et al. Immunologic and physiologic observations in baboons with life-supporting genetically-engineered pig kidney grafts. Xenotransplantation 2017;24: doi:10.1111/xen.12293.
[27] Cooper DRC, Hara H, Iwase H, et al. Justification of specific genetic modifications in pigs for clinical kidney or heart xenotransplantation. Xenotransplantation 2015;21:21361. Apr 15. doi:10.1111/xen.12156.
[28] Ezzelarab MB, Ekser B, Azimzadeh A, et al. Systemic inflammation in xenograft reciprocates preceded activation of coagulation. Xenotransplantation 2015;22:32–41.
[29] Phelps CJ, Ball SF, Vaught TD, et al. Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 2009;16:477–85.
[30] Eyestone W, Adams AB, King S, et al. Gene-edited pigs for xenotransplantation. In: Cooper DRC, Byrne GW, editors. Clinical xenotransplantation: pathways and progress in the transplantation of organs and tissues between species. New York: Springer; 2020. p. 121–40.
[31] Niu D, Wei HJ, Lin L, et al. Inactivation of porcine endogenous retrovirus in pigs. PLoS Pathog 2013;9:e1003757.
[32] Godehardt AW, Fischer N, Rauch P, et al. Characterization of porcine endogenous retrovirus particles released by the CRISPR/Cas9 inactivated cell line PK15 clone 15. Xenotransplantation 2020;27(2):e12563.
[33] Hechtendorf B, Petersen B, Knaus WA, et al. Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs. Xenotransplantation 2008;15:36–45.
[34] Ramsoordar J, Vaught T, Ball S, et al. Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs. Xenotransplantation 2009;16:164–80.
[35] Sohn B, Ostlie D, Cozzi E, et al. Growth of porcine kidneys in their native and xenograft environment. Xenotransplantation 2000;7:96–100.
[36] Iwase H, Liu H, Wijckstrom M, et al. Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date. Xenotransplantation 2015;22:320–9.
[37] Iwase H, Klein E, Cooper DRC. Physiologic aspects of pig kidney transplantation in nonhuman primates. Comp Med 2018;68:332–40.
[38] Shah JA, Tanabe T, Yamada K. Role of intrinsic factors in the growth of transplanted organs following transplantation. J Immunobiol 2017;2:122. pii. doi:10.1186/s40771-017-0139-1.
[39] Shah JA, Tanabe T, Yamada K. Role of intrinsic factors in the growth of transplanted organs following transplantation. J Immunobiol 2017;2:122. pii. doi:10.1186/s40771-017-0139-1.
[40] Hechtendorf B, Kessler B, Bührer L, et al. Distribution and expression of porcine endogenous retroviruses in multi-transgenic pigs generated for xenotransplantation. Xenotransplantation 2009;16:64–73.
[41] Bittmann I, Mihića D, Pesker R, Denner J. Expression of porcine endogenous retrovirus (PERV) in different organs of a pig. Virology 2012;443:329–36.
[42] Hinrichs A, Kessler B, Kureme M, et al. Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver, Mol Metab 2018;11:113–28.
Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenotransplantation-exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation 2015;22:211–20.

Bikhet MH, Iwase H, Yamamoto T, et al. The role of religious beliefs for the acceptance of xenotransplantation among medical providers and patients. J Ethnobiol Ethnomed 2021;17:9. doi:10.1186/s12963-021-00560-6.

Shin JS, Kim JM, Min BH, et al. Pre-clinical results in pig-to-non-human primate xenotransplantation using genetically-engineered pigs in baboons: a comparison of two immunosuppressive regimens. Transplantation 2019;103:2090–104.

Samy K, Butler J, Li P, Cooper DKC, Ekser B. The role of costimulation blockade in xenotransplantation: designated pathogen-preventive strategies to reduce and eliminate human antibody binding to class II swine leukocyte antigen epitopes. Xenotransplantation 2020;27:e12595. doi:10.1111/xen.12595.

Hinrichs A, Klymuk N, Dahlhoff M, et al. Growth hormone receptor knockout in GTFKO/hCD46/HuTM pigs as a strategy to prevent overgrowth of orthotopic xenourethral regeneration in baboons. Xenotransplantation 2019;26:e12553. Abstract 224.

Iwase H, Ball S, Adams WT, Eyeston W, Walter A, Cooper DKC. Growth hormone receptor knockout: relevance to xenotransplantation. Xenotransplantation 2020 Oct;14:e12652.

Bühler L, Avwand M, Basker M, et al. High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000;69:2296–304.

Samy K, Butler J, Li P, Cooper DKC, Ekser B. The role of costimulation blockade in solid organ and islet xenotransplantation. J Immunol Res 2017;2017:8415205. doi:10.1155/2017/8415205.

Hara H, Ezzelarab M, Rood PP, et al. Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation 2006;13:357–65.

Wong BS, Yamada K, Okumi M, et al. Allosensitization does not increase the risk of xenoreactivity to human class I lysate transfere type-knockout miniature swine in patients on transplantation waiting lists. Transplantation 2006;82:314–9.

Zhang Z, Hara H, Long C, et al. Immune responses of HLA-highly-sensitized and non-sensitized patients to genetically engineered pig organs. Transplantation 2018;102:e195–204.

Martens GR, Reyes LM, Li P, et al. Humoral reactivity of renal transplant-waitlisted patients to cells from C57BA6J/Mice and SLO class I knockout pigs. Transplantation 2017;101:e86–92.

Martens GR, Ladowski JM, Estrada J, et al. HLA class I-sensitized renal transplant patients have antibody binding to SLO class I epitopes. Transplantation 2019;103:1620–9.

Olsson D, Manook M, Yoon J, et al. Impact of allosensitization on xenosensitization. Am J Transplant 2021;21(suppl 3) https://atcmeetingabstracts.com/abstract/impact-of-allosensitization-on-xenotransplantation/ abstract Accessed June 292021.

Ladowski JM, Martens GR, Reyes LM, et al. Examining the biosynthesis and xenogenicity of class II swine leukocyte antigen proteins. J Immunol 2018;200:2957–64.

Ladowski JM, Martens GR, Reyes LM, et al. Examining epitope mutagenesis as a strategy to reduce and eliminate human antibody binding to class II swine leukocyte antigen epitopes. Immunogenetics 2019;71:477–87.

Li Q, Hara H, Zhang Z, Breimer ME, Wang Y, Cooper DKC. Is sensitization to pig antigens detrimental to subsequent allotransplantation? Xenotransplantation 2018;25:e12393. doi:10.1111/xen.12393.

Hara H, Nguyen HQ, Wang ZY, et al. Evidence that sensitization to triple-knockout pig cells will not be detrimental to subsequent allotransplantation. Xenotransplantation 2021;30:e12701. May. doi:10.1111/xen.12701.

Paris W, Mitchell C, Werkheiser Z, Lipps A, Cooper DKC, Padilla L. Public perspectives towards clinical trials of organ xenotransplantation. In: Cooper DKC, Byrne GW, editors. Clinical xenotransplantation: pathways and progress in the transplantation of organs and tissues between species. New York: Springer; 2020. p. 144–53.

Hara H, Nguyen HQ, Wang ZY, et al. Evidence that sensitization to triple-knockout pig cells will not be detrimental to subsequent allotransplantation. Xenotransplantation 2021;30:e12701. May. doi:10.1111/xen.12701.

Byrne GW, editors. Clinical xenotransplantation: pathways and progress in the transplantation of organs and tissues between species. New York: Springer; 2020. p. 144–53.

Mueller NJ, Sulling K, Gollackner B, et al. Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation. Am J Transplant 2003;3:1057–64.

Cooper DKC, Ezzelarab MB, Hara H, et al. The pathology of pig-to-primate xenotransplantation: a historical review. Xenotransplantation 2016;23:83–105.

Iwase H, Yamamoto T, Cooper DKC. Episodes of hypovolemia/dehydration in baboons with pig kidney transplants: a new syndrome of clinical importance. Xenotransplantation 2018;24:e12472. Nov 28. doi:10.1111/xen.12472.

Denner J. Detection of cell-free pig DNA using integrated PERV sequences to monitor xenotransplant tissue damage and rejection. Xenotransplantation 2021: e12688. Mar 28.

Denner J. Why was PERV not transmitted during preclinical and clinical xenotransplantation trials and after inoculation of animals? Retrovirology 2018;15(1):28. Apr 2. doi:10.1186/s12977-018-0411-8.

Jagdale A, Kumar V, Anderson DJ, et al. Suggested patient selection criteria for initial clinical trials of pig kidney xenotransplantation in the USA. Transplantation 2021 Jan 20. doi:10.1097/TP.0000000000003622.

Lucander ACK, Hara H, Nguyen HQ, Foote JB, Cooper DKC. Immunological selection and monitoring of patients undergoing pig kidney transplantation. Xenotransplantation 2021. doi:10.1111/xen.12686.

Hara H, Ezzelarab M, Rood PP, et al. Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation 2006;13:357–65.